Intravitreal Anti-vascular Endothelial Growth Factor for Newly Diagnosed Symptomatic Polypoidal Choroidal Vasculopathy with Extrafoveal Polyps
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the 12-month outcome of anti-vascular endothelial growth factor (VEGF) treatment for extrafovealpolypoidal choroidal vasculopathy (PCV). Methods: This retrospective observational study included 32 eyes of 32 patients newly diagnosed with extrafovealPCV (polyps located more than 500 μm from the center of the fovea). Patients were treated with intravitrealranibizumab, bevacizumab, or both. The best-corrected visual acuity (BCVA) and central foveal thickness(CFT) at diagnosis and at 12 months were compared. Eyes were divided into two groups according to thepresence of submacular hemorrhage. The BCVA in each group was compared at baseline and at 12 months. Results: During the 12-month study period, patients received an average of 4.0 ± 1.1 anti-VEGF injections. TheBCVA at baseline, three-month post-diagnosis, and 12-month post-diagnosis was 0.59 ± 0.40, 0.34 ± 0.38,and 0.38 ± 0.38, respectively. The BCVA at 12 months was significantly better than the baseline value (p =0.002). The CFT at baseline, three-month, and 12-month post-diagnosis was 477.1 ± 194.2 μm, 214.5 ± 108.8μm, and 229.8 ± 106.1 μm, respectively. The CFT at 12 months was significantly lower than the baseline value(p < 0.001). A significant improvement in BCVA was noted in eyes with and without submacular hemorrhage (n= 13, p = 0.032 and n = 19, p = 0.007, respectively). Conclusions: Anti-VEGF therapy was beneficial in extrafoveal PCV, regardless of the presence of submacularhemorrhage.
Abstract
Purpose: To evaluate the 12-month outcome of anti-vascular endothelial growth factor (VEGF) treatment for extrafovealpolypoidal choroidal vasculopathy (PCV). Methods: This retrospective observational study included 32 eyes of 32 patients newly diagnosed with extrafovealPCV (polyps located more than 500 μm from the center of the fovea). Patients were treated with intravitrealranibizumab, bevacizumab, or both. The best-corrected visual acuity (BCVA) and central foveal thickness(CFT) at diagnosis and at 12 months were compared. Eyes were divided into two groups according to thepresence of submacular hemorrhage. The BCVA in each group was compared at baseline and at 12 months. Results: During the 12-month study period, patients received an average of 4.0 ± 1.1 anti-VEGF injections. TheBCVA at baseline, three-month post-diagnosis, and 12-month post-diagnosis was 0.59 ± 0.40, 0.34 ± 0.38,and 0.38 ± 0.38, respectively. The BCVA at 12 months was significantly better than the baseline value (p =0.002). The CFT at baseline, three-month, and 12-month post-diagnosis was 477.1 ± 194.2 μm, 214.5 ± 108.8μm, and 229.8 ± 106.1 μm, respectively. The CFT at 12 months was significantly lower than the baseline value(p < 0.001). A significant improvement in BCVA was noted in eyes with and without submacular hemorrhage (n= 13, p = 0.032 and n = 19, p = 0.007, respectively). Conclusions: Anti-VEGF therapy was beneficial in extrafoveal PCV, regardless of the presence of submacularhemorrhage.
참고문헌 (30)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- Martin DF, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
- 장용석, "Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity", Korean Journal of Ophthalmology, 28(6), pp.466~472 (2014), 대한안과학회
- 권윤형, "Predictive Findings of Visual Outcome in Spectral Domain Optical Coherence Tomography after Ranibizumab Treatment in Age-related Macular Degeneration", Korean Journal of Ophthalmology, 28(5), pp.386~392 (2014), 대한안과학회
- Parodi MB, "Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration", Retina, 34, pp.2167~2170 (2014)
- Ladas ID, "Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration", Ophthalmologica, 228, pp.93~101 (2012)
- Kokame GT, "Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy:6-month results", Br J Ophthalmol, 94, pp.297~301 (2010)
- Oishi A, "Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results", Am J Ophthalmol, 156, pp.644~651 (2013)
- Sun Young Lee, "The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal Vasculopathy", Korean Journal of Ophthalmology, 22(2), pp.92~99 (2008), 대한안과학회
- 조한주, "Short-term Effectiveness of Intravitreal Bevacizumab vs. Ranibizumab Injections for Patients with Polypoidal Choroidal Vasculopathy", Korean Journal of Ophthalmology, 26(3), pp.157~162 (2012), 대한안과학회[DOI]
- Gemmy Cheung CM, "Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy", Am J Ophthalmol, 155, pp.295~304 (2013)
- Cackett P, "A classification system for polypoidal choroidal vasculopathy", Retina, 29, pp.187~191 (2009)
- Koh AH, "Polypoidal choroidal vasculopathy:evidence-based guidelines for clinical diagnosis and treatment", Retina, 33, pp.686~716 (2013)
- Giacomelli G, "Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration", Retina, 34, pp.860~867 (2014)
- Lafaut BA, "Polypoidal choroidal vasculopathy in Caucasians", Graefes Arch Clin Exp Ophthalmol, 238, pp.752~759 (2000)
- Yuzawa M, "A study of laser photocoagulation for polypoidal choroidal vasculopathy", Jpn J Ophthalmol, 47, pp.379~384 (2003)
- Gomez-Ulla F, "Diode laser photocoagulation in idiopathic polypoidal choroidal vasculopathy", Retina, 18, pp.481~483 (1998)
- Lee MW, "Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy", Eye (Lond), 23, pp.145~148 (2009)
- Hirami Y, "Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy", Retina, 27, pp.335~341 (2007)
- Isola V, "Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization", Am J Ophthalmol, 142, pp.680~683 (2006)
- Goldstein M, "Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD", Eye (Lond), 19, pp.1315~1324 (2005)
- Schnurrbusch UE, "Complications after photodynamic therapy", Arch Ophthalmol, 123, pp.1347~1350 (2005)
- Oluleye T, "Pattern of presentation of idiopathic polypoidal choroidal vasculopathy in Ibadan, Sub-Saharan Africa", Clin Ophthalmol, 7, pp.1373~1376 (2013)
- Cheng CK, "One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy", Retina, 31, pp.846~856 (2011)
- Hikichi T, "One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients", Am J Ophthalmol, 154, pp.117~124 (2012)
- Lai TY, "Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy", Retina, 31, pp.1581~1588 (2011)
- Tsujikawa A, "Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab", Jpn J Ophthalmol, 54, pp.310~319 (2010)
- Kang HM, "Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy", Am J Ophthalmol, 156, pp.652~660 (2013)
- Hikichi T, "Factors predictive of outcomes 1 year after 3 monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients", Retina, 33, pp.1949~1958 (2013)
- De Salvo G, "Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy", Am J Ophthalmol, 158, pp.1228~1238 (2014)